| Antibiotic Resistance in Bacteria | Lifetime | 13 | ES 1 | 99.93 |
| Antibiotics Pharmacokinetics and Efficacy | Lifetime | 20 | ES 2 | 99.83 |
| Antibiotic Use and Resistance | Lifetime | 15 | ES 1 | 99.83 |
| Enterobacteriaceae and Cronobacter Research | Lifetime | 5 | ES 1 | 99.74 |
| Bacterial Identification and Susceptibility Testing | Lifetime | 28 | ES 2 | 99.74 |
| Pneumonia and Respiratory Infections | Lifetime | 84 | ES 4 | 99.59 |
| Bacterial biofilms and quorum sensing | Lifetime | 61 | ES 1 | 99.49 |
| Infections and bacterial resistance | Lifetime | 10 | ES 1 | 99.52 |
| Antifungal resistance and susceptibility | Lifetime | 83 | ES 5 | 99.50 |
| Cystic Fibrosis Research Advances | Lifetime | 67 | ES 2 | 99.11 |
| Antimicrobial Resistance in Staphylococcus | Lifetime | 117 | ES 3 | 99.35 |
| Pharmaceutical and Antibiotic Environmental Impacts | Lifetime | 163 | ES 26 | 99.18 |
| Fungal Infections and Studies | Lifetime | 155 | ES 8 | 98.82 |
| Urinary Tract Infections Management | Lifetime | 265 | ES 5 | 98.03 |
| Nosocomial Infections in ICU | Lifetime | 176 | ES 16 | 98.22 |
| Mycobacterium research and diagnosis | Lifetime | 616 | ES 18 | 97.21 |
| Vibrio bacteria research studies | Lifetime | 349 | ES 15 | 97.53 |
| Streptococcal Infections and Treatments | Lifetime | 550 | ES 12 | 97.13 |
| Pneumocystis jirovecii pneumonia detection and treatment | Lifetime | 600 | ES 23 | 97.10 |
| Nail Diseases and Treatments | Lifetime | 562 | ES 14 | 95.97 |
| Nephrotoxicity and Medicinal Plants | Lifetime | 528 | ES 11 | 74.91 |
| Historical Medical Research and Treatments | Lifetime | 804 | ES 13 | 52.54 |
| Antibiotic Resistance in Bacteria | 2021-2025 | 2 | ES 1 | 99.86 |
| Antibiotic Use and Resistance | 2021-2025 | 2 | ES 1 | 99.75 |
| Bacterial Identification and Susceptibility Testing | 2021-2025 | 5 | ES 1 | 99.68 |
| Antibiotics Pharmacokinetics and Efficacy | 2021-2025 | 6 | ES 1 | 99.59 |
| Infections and bacterial resistance | 2021-2025 | 1 | ES 1 | 99.04 |
| Pneumonia and Respiratory Infections | 2021-2025 | 62 | ES 4 | 98.14 |
| Urinary Tract Infections Management | 2021-2025 | 106 | ES 2 | 93.83 |
| Bacterial biofilms and quorum sensing | 2021-2025 | 250 | ES 11 | 91.57 |
| Nosocomial Infections in ICU | 2021-2025 | 144 | ES 14 | 90.77 |
| Cystic Fibrosis Research Advances | 2021-2025 | 340 | ES 16 | 92.13 |
| Antimicrobial Resistance in Staphylococcus | 2021-2025 | 447 | ES 26 | 87.67 |
| Antifungal resistance and susceptibility | 2021-2025 | 724 | ES 33 | 87.29 |
| Respiratory and Cough-Related Research | 2021-2025 | 678 | ES 25 | 80.57 |
| Enterobacteriaceae and Cronobacter Research | 2021-2025 | 132 | ES 2 | 76.34 |
